NEW YORK (GenomeWeb News) – Becton Dickinson today reported fourth-quarter revenue growth of around 11 percent, with double-digit growth coming from all three of its operating segments.
The Franklin Lakes, NJ-based firm brought in total revenues of $1.83 billion for the three-month period ended Sept. 30, up from $1.65 billion in the comparable period of 2007. Sales for BD Medical rose around 10 percent year over year to $953.1 million, while sales for BD Diagnostics increased 11 percent to $553.1 million from $497.9 million, and sales for BD Biosciences rose 16 percent to $329.5 million from $284.9 million.
Within BD Biosciences, sales for its cell analysis products rose 16 percent to $98.9 million from $85.1 million, and sales for its discovery labware products fell 6 percent to $37.9 million from $40.2 million.
BD’s net income for the quarter increased roughly 9 percent to $282.2 million, or $1.12 per share, from $259.8 million, or $1.03 per share.
Its R&D spending in the quarter rose 8 percent to $108.6 million from $100.4 million year over year, and its SG&A costs increased roughly 9 percent to $437.2 million from $399.5 million.
For full-year 2008, BD reported a 12 percent increase in revenues to $7.16 billion from $6.36 billion. Sales for BD Medical Products rose 11 percent to $3.8 billion from $3.4 billion, while sales for BD Diagnostics increased 13 percent to $2.2 billion from $1.9 billion, and sales for BD Biosciences climbed around 16 percent to $1.2 billion from $1 billion.
The firm’s FY2008 profit was $1.13 billion, or $4.46 per share, compared to $890 million, or $3.49 per share, for fiscal 2007. Its SG&A expenses increased 7 percent to $1.7 billion from $1.6 billion, and its R&D spending rose 10 percent to $396.2 million from $360 million.
BD did not provide its cash position as of Sept. 30.
It said that it expects fiscal 2009 revenues to increase around 1 percent to 2 percent over 2008, with unfavorable foreign currency translation of an estimated 5 percent to 6 percent.